An observational study in Lung Cancer, NSCLC Stage IV and NSCLC, Stage III, sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Completed at 3 sites in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Lung Neoplasms with a site in Austria — 17 open to participants now, 22 under way, 10 of them phase 3. Lung Neoplasms · Austria.
Among the 69 studies in Lung Neoplasms with a site in Austria, this one is the 14th largest by enrollment of the 17 observational ones that give a count, is one of 3 that started in 2020, is one of 17 observational ones, and was the 44th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →17 of the 69 studies in Lung Neoplasms with a site in Austria are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Austria, United States, Argentina and 31 more countries
Ages 18+
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Sites in Austria, Germany
Ages 18+
University of Vienna · Sites in Austria
Ages 18+
Pfizer · Sites in Austria, United States, Argentina and 28 more countries
Ages 18+
Nuvalent Inc. · Sites in Austria, United States, Argentina and 26 more countries
Ages 18+
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 12 · Phase 3 29 · Phase 4 1
First in 1995; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 290 is above the median of 200 across 1,436 observational studies indexed under Lung Neoplasms.
Median enrollment 368 across the 52 interventional studies, 770 across the 17 observational. Of the 42 that completed or were terminated, 24 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 69 have an industry lead sponsor. The 10 most frequent:
Arbeitsgemeinschaft medikamentoese Tumortherapie is the lead sponsor of 43 studies on the registry; 4 are open to participants now.
Arbeitsgemeinschaft medikamentoese Tumortherapie has 2 studies filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
10 of the studies in Lung Neoplasms with a site in Austria that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06151574Phase 3Boehringer IngelheimBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | 2026-12-10 |
| NCT05920356Phase 3AmgenA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | 2027-06-30 |
| NCT06635824Phase 3GenmabTrial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) | 2027-07-30 |
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
| NCT01789229Medical University of ViennaEstablishment of a Tumor Bank for Tissue Samples | 2026-12 |
Add all 10 to your calendar (.ics) → With an account.
Among the 69 studies in Lung Neoplasms with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Lung cancer is the second most common cancer in Austria with 2.868 men and 2.009 women diagnosed in 2016. Reflecting the high mortality of this disease, 2.415 men and 1.534 women died from lung cancer. Therefore, lung cancer is the most common reason for cancer associated death in men and second most common reason in women.
This malignant disease can be divided into two main groups: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is a paradigm for personalized medicine, with an increasing number of targetable gene alterations. Despite this growing diversity of molecular subtypes, in most patients no targetable mutation can be detected. For these patients check-point inhibitors with or without chemotherapy is the mainstay of the initial tumor therapy. Until recently, little progress has been made in the treatment of SCLC in last decades. Recently, an overall survival benefit by the addition of an immune-checkpoint inhibitor to first-line chemotherapy for advanced SCLC has been reported.
Despite the progress in the treatment of NSCLC, the performance of predictive biomarkers is weak. Therefore, the development of more precise prediction models is of great importance for the progress of personalized treatment strategies.
This registry is designed as multicenter observational cohort of patients with lung cancer. Patient medical, testing and treatment information will be obtained through extraction of data from existing patient medical charts. Longitudinal follow-up data, including survival and tumor progression, will also be extracted from patient medical charts. This patient follow-up data will be obtained until patient death or loss to follow-up.
For documentation in the registry, no further diagnostic or therapeutic measures are required than those already necessary in general. Participation in the registry must not interfere with treatment routines. Only routine data, which has already been recorded in the patient's medical chart, is transferred to the electronic Case Report Forms. To maintain patient confidentiality, each patient will be assigned a unique patient identifying number upon enrollment; this number will accompany the patient's medical and other registry information throughout the lifetime of the registry.
A written consent must be obtained prior to the input of data. No informed consent is required from deceased patients.
Data will be collected from all sites willing to participate.
The registry will be made available for all disciplines and physicians caring for cancer patients with locally advanced or metastatic lung cancer in Austria. In a first step patients with diagnosis after 01.01.2019 will be included. In a second step the registry will be expanded to include patients with diagnosis before 01.01.2019.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Due to the non-interventional design of the registry there are no specific exclusion criteria.
General characteristics
To describe the general characteristics of advanced or metastatic stage patients in Austria (Stage III A-C and IV A-B NSCLC, limited disease (LD) and extensive disease (ED) SCLC)
Time frame: 10 years
Molecular testing
To describe molecular testing in patients with advanced or metastatic lung cancer * number of patients with molecular testing * methods for molecular testing * number of patients with PD-L1 testing * PD-L1 % range per disease stage * PD-L1 test antibody used * number of genes tested * number of patients with at least one mutation identified * number of patients with at least one druggable target identified
Time frame: 10 years
Characterize subgroups
To describe and characterize subgroups * Number of patients with NSCLC * Number of patients that receive immune-checkpoint inhibitors * Number of patients with targetable/druggable mutations
Time frame: 10 years
Treatment duration
To describe duration of treatment
Time frame: 10 years
Treatment frequency
To describe frequency of treatment
Time frame: 10 years
Degree of treatment response
To describe degree of treatment response in %
Time frame: 10 years
Treatment sequence
To describe sequence of use of various treatments
Time frame: 10 years
Outcome OS
To describe patient outcome by means of overall survival (OS) in %
Time frame: 10 years
Outcome PFS
To describe patient outcome by means of progression free survival (PFS) in %
Time frame: 10 years
Plan to share: No — The datasets generated and/or analyzed during the current study are not publicly available but are available from AGMT (Austrian Group Medical Tumor Therapy) upon reasonable request. Requests for access to these data should be directed to AGMT via office@agmt.at.
No publications or documents are linked to this record.
Ran from Aug 2020 to primary completion in May 2026, 68 months.
Of 592 non-industry observational studies under Lung Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 162. This study's 68 months is close to that.
Counting every sponsor, half of 682 studies reached it within 57 months; a quarter within 25 and three quarters within 135.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Aug 2030 → May 2026 and completion Aug 2030 → May 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Arbeitsgemeinschaft medikamentoese Tumortherapie